loxoprofen has been researched along with Gastroduodenal Ulcer in 5 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib 100 mg b." | 6.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse events (AEs)." | 2.78 | Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. ( Kinoshita, Y; Miwa, H; Sugano, K; Takeuchi, T, 2013) |
| "Celecoxib 100 mg b." | 2.78 | Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. ( Kawai, T; Nakamura, S; Sakamoto, C; Sugioka, T; Tabira, J, 2013) |
| "Omeprazole (100 mg/kg) was given p." | 1.36 | Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats. ( Amagase, K; Kato, S; Ochi, A; Sugihara, T; Takeuchi, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 1 |
| Amagase, K | 2 |
| Yoshida, Y | 1 |
| Hara, D | 1 |
| Murakami, T | 1 |
| Takeuchi, K | 2 |
| Ochi, A | 1 |
| Sugihara, T | 1 |
| Kato, S | 1 |
| Sakamoto, C | 1 |
| Kawai, T | 1 |
| Nakamura, S | 1 |
| Sugioka, T | 1 |
| Tabira, J | 1 |
| Ise, Y | 1 |
| Murota, Y | 1 |
| Takayama, K | 1 |
| Narita, M | 1 |
| Suzuki, T | 1 |
| Soh, S | 1 |
| Katayama, S | 1 |
| Hirano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects[NCT00994461] | Phase 4 | 190 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
The percentage of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastroduodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 1.4 |
| Loxoprofen | 27.6 |
| Placebo | 2.7 |
The percentage of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment (The number of subjects who had treatment-emergent, all-causality gastrointestinal body system adverse events after 2 weeks treatment divided by participants multiplied by 100.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) |
|---|---|
| Celecoxib | 24.3 |
| Loxoprofen | 47.4 |
| Placebo | 16.2 |
The percentage of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment (The number of subjects who had gastric and duodenal endoscopic ulcers after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | |
|---|---|---|
| Gastric ulcers | Duodenal ulcers | |
| Celecoxib | 0 | 1.4 |
| Loxoprofen | 25.0 | 5.3 |
| Placebo | 2.7 | 0 |
The percentage of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment (The number of subjects who had gastroduodenal, gastric, and duodenal endoscopic ulcers and/or erosions after 2 weeks treatment divided by participants multiplied by 100.) An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth. An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth. (NCT00994461)
Timeframe: 2 weeks
| Intervention | Percent (Number) | ||
|---|---|---|---|
| Gastroduodenal ulcers and/or erosions | Gastric ulcers and/or erosions | Duodenal ulcers and/or erosions | |
| Celecoxib | 36.5 | 35.1 | 4.1 |
| Loxoprofen | 53.9 | 53.9 | 5.3 |
| Placebo | 24.3 | 24.3 | 0 |
Number of subjects for each number of gastroduodenal endoscopic erosions after 2 weeks treatment (An erosion is defined as a lesion producing a definite break in the mucosa with equivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 erosion | 1 erosion | 2 erosions | 3 erosions | 4 erosions | 5 erosions | 6 erosions | 7 erosions | 8 erosions | 9 erosions | 10 or more erosions | |
| Celecoxib | 47 | 14 | 4 | 5 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Loxoprofen | 41 | 13 | 3 | 9 | 4 | 3 | 1 | 1 | 1 | 0 | 0 |
| Placebo | 29 | 5 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each number of gastroduodenal endoscopic ulcers after 2 weeks treatment (An ulcer is defined as any break in the mucosa at least 3 mm in diameter with unequivocal depth.) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 ulcer | 1 ulcer | 2 ulcers | 3 ulcers | 4 ulcers | 5 ulcers | 6 ulcers | 7 ulcers | 8 ulcers | 9 ulcers | 10 or more ulcers | |
| Celecoxib | 73 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Loxoprofen | 55 | 10 | 5 | 2 | 0 | 0 | 1 | 2 | 1 | 0 | 0 |
| Placebo | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects for each gastroduodenal endoscopic score (according to Mucosal Grading Scale) after 2 weeks treatment (Score 0 = normal mucosa (no visible lesions); Score 1 = 1 to 10 petechiae; Score 2 = more than 10 petechiae; Score 3 = 1 to 5 erosions; Score 4 = 6 to 10 erosions; Score 5 = 11 to 25 erosions; Score 6 = more than 25 erosions; Score 7 = ulcer) (NCT00994461)
Timeframe: 2 weeks
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Score 0 | Score 1 | Score 2 | Score 3 | Score 4 | Score 5 | Score 6 | Score 7 | |
| Celecoxib | 38 | 8 | 1 | 22 | 4 | 0 | 0 | 1 |
| Loxoprofen | 33 | 2 | 0 | 19 | 1 | 0 | 0 | 21 |
| Placebo | 22 | 6 | 0 | 8 | 0 | 0 | 0 | 1 |
2 trials available for loxoprofen and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |
Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloo | 2013 |
3 other studies available for loxoprofen and Gastroduodenal Ulcer
| Article | Year |
|---|---|
Prophylactic effect of egualen sodium, a stable azulene derivative, on gastrointestinal damage induced by ischemia/reperfusion, double antiplatelet therapy and loxoprofen in rats.
Topics: Animals; Aspirin; Azulenes; Benzoquinones; Clopidogrel; Gastric Mucosa; Gastrointestinal Hemorrhage; | 2013 |
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.
Topics: 16,16-Dimethylprostaglandin E2; Acetamides; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer A | 2010 |
[The analysis of prescription frequency and the factors on adverse reactions of NSAIDs for post-operative pain in orthopedic patients].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cost Savings; Drug Prescriptions; Female; Heal | 2003 |